Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2025Current Drug Metabolism

Metabolomics and Network Pharmacology Analyses of Yiqi Huazhuo Decoction in Regulating EGFR Signaling and Metabolic Pathways in Type 2 Diabetes with Insulin Resistance: In Vivo Validation

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSinan LiJLJiaying LiuSWSiying Weng

Discussion

Loading...

Member takes

Overview

Animal study demonstrates improved metabolic pathways in type 2 diabetes, indicating potential for EGFR modulation.

Key Points

  • YD improved insulin sensitivity and hepatic function in a type 2 diabetes model, showcasing its metabolic benefits.
  • Luteolin binding to EGFR enhances PI3K-Akt signaling, as indicated by multi-omics analysis identifying key metabolic changes.
  • Network pharmacology analysis highlighted YD’s multi-target mechanism, setting it apart from single-target therapies.
  • The study provides robust insights into YD's role in regulating insulin resistance and lipid metabolism in diabetes.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d909fc41e1c178a14f5b08https://doi.org/10.2174/0113892002424452250905064705
View Full Paper
Ask AI
Bookmark
Share